The N-butyl indazole derivative, N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (ADB-BUTINACA or ADB-BINACA), currently a drug of abuse in Russia, is reported to have a cannabinoid receptor potency and efficacy almost three times higher than JWH-018. ADB-BUTINACA was detected in blood from patients with suspected drug intoxications, as well as in blood, kidney and liver samples collected during postmortem investigations. Using liquid chromatography–time-of-flight–mass spectrometry, a number of ADB-BUTINACA metabolites were tentatively identified in urine samples. These include products of mono- and dihydroxylation, hydroxylation of the N-butyl side chain and dehydrogenation, formation of a dihydrodiol, hydrolysis of the terminal amide group, N-dealkylation of the indazole and a combination of these reactions. The dihydrodiol was found to be the predominant metabolite, with its chromatographic peak area exceeding those of other metabolites by almost an order of magnitude. For the routine analysis of blood, liver and kidney samples, the dihydrodiol and monohydroxylated metabolites along with the parent compound are recommended as target analytes. The same metabolites in free and glucuronidated forms are also recommended for analytical confirmation in urine samples.

中文翻译：

---

检测人类尿液、血液、肾脏和肝脏中的 ADB-BUTINACA 代谢物

N-丁基吲唑衍生物，N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (ADB-BUTINACA 或 ADB-BINACA)，目前在俄罗斯被滥用的药物，据报道其大麻素受体效力和功效几乎是 JWH-018 的三倍。ADB-BUTINACA 在疑似药物中毒患者的血液中以及在死后调查期间收集的血液、肾脏和肝脏样本中检测到。使用液相色谱-飞行时间-质谱法，初步鉴定了尿液样品中的一些 ADB-BUTINACA 代谢物。这些包括单羟基化和二羟基化的产物、N-丁基侧链的羟基化和脱氢、二氢二醇的形成、末端酰胺基团的水解、吲唑的N-脱烷基化以及这些反应的组合。二氢二醇被发现是主要的代谢物，其色谱峰面积超过其他代谢物几乎一个数量级。对于血液、肝脏和肾脏样本的常规分析，建议将二氢二醇和单羟基化代谢物以及母体化合物作为目标分析物。还建议将游离和葡萄糖醛酸化形式的相同代谢物用于尿样中的分析确认。